Metastatic Colorectal Cancer，NED
Conditions
Keywords
Metastatic Colorectal Cancer，NED
Brief summary
Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED). However, these patients have a high risk of developing persistent cancer. This study aimed to investigate the efficacy and safety of Tislelizumab combined with capecitabine as a maintenance treatment for patients with mCRC-NED.
Detailed description
This is a Phase 2, randomized, open-label, single-center study designed to compare the efficacy and safety of tislelizumab+ capecitabine versus best-supported care as a first-line maintenance treatment in participants with mCRC-NED. Patients who underwent synchronously or staged removal of primary and metastatic lesions, achieving NED, and histologically confirmed colorectal adenocarcinoma were recruited in this trial. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and adverse events. This study will provide novel data on the efficacy and safety profile of the combination of tislelizumab and capecitabine in patients with mCRC-NED.
Interventions
DRUGTislelizumab + Capecitabine
Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy. Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy.
OTHERBest supportive care
Best supportive care
Sponsors
Yanhong Deng
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 20 years, \< 80 years 2. Written informed consent 3. Histologically or cytologically confirmed CRC 4. Surgery with integrated treatment for metastatic colorectal cancer (mCRC) and achieved a statute of no evidence of disease (NED), as determined by a multidisciplinary tumor board. 5. cytoreduction surgery achieves CC0 (no visible residual tumor) if there is peritoneal metastasis 6. No previous chemotherapy 7. Synchronous or metachronous metastatic disease: maximum of two distant organs or regions involved 8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 9. Adequate hematologic and organ function
Exclusion criteria
1. Presence of any other active cancer 2. Presence of active infections requiring antibiotics 3. History of active autoimmune disease requiring systemic treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | 36 months | The time from NED to the first occurrence of any of the following events: local relapse, distant metastasis, or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 60 months | The time from NED to death from any cause |
| Adverse events | 60 months | Side effect of both agents |
Countries
China
Outcome results
None listed